申请人:Merck & Co., Inc.
公开号:US05196411A1
公开(公告)日:1993-03-23
17.beta.-acyl-3-carboxy-androsta-3,5-dienes as testosterone 5.alpha.-reductase inhibitors of the formula: ##STR1## wherein R is C.sub.3 -C.sub.8 cycloalkyl, which can be substituted with C.sub.1 -C.sub.4 alkoxy or C.sub.6 -C.sub.12 aryl, which can be substituted with one or more of: --OH, --OC.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkyl, --(CH.sub.2).sub.m OH, --(CH.sub.2).sub.n COOH, including protected --OH, where m is 1-4, n is 1-3, and pharmaceutically acceptable salts or esters thereof. Also described is a pharmaceutical formulation. The above compounds are active as testosterone 5.alpha.-reductase inhibitors and thus are useful topically for treatment of acne, seborrhea, female hirsutism, and systemically in treatment of benign prostatic hypertrophy.
17-beta-酰-3-羧基-雄甾-3,5-二烯酮作为雄激素5-alpha-还原酶抑制剂的化学式为:其中R是C.sub.3 -C.sub.8环烷基,可以用C.sub.1 -C.sub.4烷氧基或C.sub.6 -C.sub.12芳基取代,可以取代为一个或多个:-OH,-OC.sub.1 -C.sub.4烷基,C.sub.1 -C.sub.4烷基,-(CH.sub.2).sub.m OH,-(CH.sub.2).sub.n COOH,包括保护的-OH,其中m为1-4,n为1-3,以及其药学上可接受的盐或酯。还描述了一种药物配方。上述化合物作为雄激素5-alpha-还原酶抑制剂具有活性,因此在治疗痤疮、皮脂溢、女性多毛症的局部治疗以及在治疗良性前列腺增生方面具有系统性应用。